Evidence supporting the use of: Acetyl l-carnitine
For the health condition: Neuralgia and Neuritis

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Acetyl L-carnitine (ALC) has scientific evidence supporting its use for certain types of neuralgia and neuritis, particularly in the context of peripheral neuropathy and nerve pain associated with conditions like diabetes and chemotherapy-induced neuropathy. ALC is a naturally occurring derivative of L-carnitine that plays a role in mitochondrial energy production and has neuroprotective properties. Several clinical studies and meta-analyses indicate that ALC supplementation can reduce pain and improve nerve fiber regeneration in patients with peripheral neuropathy.

For example, randomized controlled trials have demonstrated that ALC (typically at doses of 500–3,000 mg per day) may lead to significant reductions in pain scores and improvements in nerve function, especially in diabetic and HIV-associated neuropathy. A 2005 study published in Diabetes Care and a 2010 meta-analysis in CNS Drugs both concluded that ALC is superior to placebo for improving both pain and sensory function in neuropathic patients. Its mechanism is thought to involve enhancement of nerve growth factor, mitochondrial function, and possible modulation of neurotransmitters.

However, the strength of evidence varies depending on the etiology of neuralgia or neuritis, with the best data for diabetic and chemotherapy-induced neuropathy. While ALC is generally well-tolerated, more large-scale, high-quality trials are needed to establish its efficacy across broader types of neuralgia and neuritis. Nonetheless, its use is supported by a moderate level of scientific evidence, particularly in specific neuropathic populations.

More about acetyl l-carnitine
More about Neuralgia and Neuritis